Share the post "Mutual Fund Data: Stock Market today Insights for – 22 Aug 2024"
| Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Kalyan Jewellers India | Motilal Oswal Mutual Fund | Buy | 9M | 539.10 | Highdell Investment |
The 9M shares of Kalyan Jewellers India have been purchased by the by Motilal Oswal Mutual Fund through mutual funds at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
| Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Alkem Laboratories | Icici Prudential Life Insurance Company | Buy | 197K | 5732.15 | Samprada&nanhamati Singh Family Trust |
| Iti Mutual Fund | Buy | 50K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
| Jm Financial Mutual Fund | Buy | 17K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
| Kotak Mahindra Mutual Fund | Buy | 61K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
|
Kalyan Jewellers India | Motilal Oswal Mutual Fund | Buy | 9M | 539.10 | Highdell Investment |
| Sundaram Mutual Fund | Buy | 1M | 539.10 | Highdell Investment |
Alkem Laboratories shares totaling 197K were purchased by the by Icici Prudential Life Insurance Company of MutualFund, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 50K were purchased by the by Iti Mutual Fund of MutualFund, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 17K were purchased by the by Jm Financial Mutual Fund of MutualFund, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Alkem Laboratories shares totaling 61K were purchased by the by Kotak Mahindra Mutual Fund of MutualFund, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 9M were purchased by the by Motilal Oswal Mutual Fund of MutualFund, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Kalyan Jewellers India shares totaling 1M were purchased by the by Sundaram Mutual Fund of MutualFund, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Kalyan Jewellers India Limited
55,354.79
Net Sales
1,775.58
Net Profit
55,576.37
Total Income
53,201.46
Expenditure
643
Current Price
66,324
Market Cap
For Kalyan Jewellers India Limited, the latest financial data showcases impressive results. The company reported net sales of ₹55,354.79 million and total income of ₹55,576.37 million for the quarter. Expenditure was ₹53,201.46 million, resulting in a net profit of ₹1,775.58 million. EPS for continuing operations was ₹1.73. Additional financial details include other income of ₹221.58 million, finance costs of ₹852.25 million, and employee benefit expenses of ₹1,724.32 million. Depreciation and amortization expenses were ₹754.69 million. Current tax was ₹894.99 million and deferred tax amounted to ₹-295.66 million. Total comprehensive income for the period was ₹1,757.02 million, with other comprehensive income net of taxes at ₹-18.56 million.
The company's market cap is ₹66,324 crore, with a stock price of ₹643. The historical stock range has been between ₹663 / 203. Its Price-to-Earnings (P/E) ratio of 105 indicates a high valuation. The book value per share is ₹40.7, and it has a dividend yield of 0.19%. The ROCE is 14.0% and ROE is 15.2%. With a very low debt-to-equity ratio of 1.07, the company is minimally leveraged. However, it reports a negative net cash flow of ₹36.8 crore. The Piotroski score of 7.00 and the Graham Number of ₹74.9 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 15.8 suggests the stock is trading at a premium.
Alkem Laboratories Limited
25,001.00
Net Sales
5,832.50
Net Profit
26,062.00
Total Income
19,652.60
Expenditure
6,310
Current Price
75,445
Market Cap
The financial snapshot for Alkem Laboratories Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹25,001.00 million and total income was ₹26,062.00 million. The company's expenditure was ₹19,652.60 million, leading to a net profit of ₹5,832.50 million. Earnings per Share (EPS) for continuing operations were ₹48.78. The report also highlights other income of ₹1,061.00 million, finance costs of ₹214.40 million, and employee benefit expenses of ₹4,259.00 million. Depreciation and amortization costs were ₹643.50 million, while current and deferred taxes were ₹1,112.60 million and ₹-535.70 million, respectively. The total comprehensive income for the period stood at ₹5,807.70 million, with other comprehensive income net of taxes at ₹-24.80 million.
With a market capitalization of ₹75,445 crore, the company’s stock is currently priced at ₹6,310. The historical trading range of the stock is ₹6,347 / 3,440. The P/E ratio is remarkably high at 35.2, suggesting a significant valuation. The book value stands at ₹862, and the dividend yield is 0.63%. The Return on Capital Employed (ROCE) is 19.7%, and the Return on Equity (ROE) is 19.6%. The debt-to-equity ratio is very low at 0.14, though the company shows a negative net cash flow of ₹-207 crore. The Piotroski score is 9.00, with the Graham Number pegged at ₹1,826. The Price-to-Book (P/B) ratio of 7.32 highlights a premium valuation.
